Pathogenic and dysbiotic gut bacteria

Pathogenic and dysbiotic gut bacteria represent a collective therapeutic target consisting of harmful or imbalanced microbial populations within the human gastrointestinal tract. Dysbiosis is defined by a reduction in microbial diversity and the overgrowth of opportunistic pathogens, which disrupts the symbiotic relationship between the host and its microbiota (Source: NIH, PMC3448089). These bacteria contribute to disease by compromising the intestinal barrier, producing pro-inflammatory metabolites, and interfering with normal metabolic processes. This target is central to the pathogenesis of conditions such as Clostridioides difficile infection, inflammatory bowel disease, and certain metabolic disorders (Source: Nature Reviews Microbiology, 2022). Therapeutic strategies targeting this entity include the use of narrow-spectrum antibiotics to eliminate specific pathogens and live biotherapeutic products or fecal microbiota transplantation to restore a healthy microbial ecosystem (Source: FDA, 2023). By modulating the composition and function of the gut microbiota, these treatments aim to re-establish homeostasis and mitigate the systemic effects of microbial imbalance.

Other names

Gut microbiotaGut microbiomeDysbiotic floraEnteric pathogensIntestinal dysbiosis

Drugs targeting pathogenic and dysbiotic gut bacteria function through several mechanisms: antibiotics exert bactericidal or bacteriostatic effects by inhibiting cell wall synthesis or protein synthesis in specific pathogens; live biotherapeutic products and fecal microbiota transplants restore ecological balance through competitive exclusion, production of antimicrobial peptides, and restoration of secondary bile acid metabolism (Source: PubMed, 37133530; FDA, 2023).